CNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CNX is not a good immediate buy for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has weak technical momentum, no bullish proprietary signal, cautious analyst coverage, and negative hedge fund flow. While options sentiment is bullish and the commodity backdrop has supportive elements, the overall setup is not strong enough for an impatient buyer to commit aggressively right now. Best direct call: hold and wait for a clearer trend improvement or a better entry.
CNX is trading at 33.7, slightly below the previous close of 33.93. The MACD histogram is -0.186 and still deteriorating, which points to weakening momentum. RSI_6 at 25.328 is deeply oversold/weak, but not yet a clean reversal signal on its own. Moving averages are converging, suggesting the stock is at an inflection point rather than in a confirmed uptrend. Price is below the pivot level of 35.568 and only slightly above S1 at 34.011 and S2 at 33.049, so support is close but trend confirmation is lacking. Short-term pattern data also points negative, with a projected -3.79% next week and -4.02% next month. No AI Stock Picker signal and no SwingMax signal means there is no Intellectia-backed entry trigger today.
["Options sentiment is strongly bullish, with very low put-call ratios and call-heavy activity.", "The broader analyst commentary suggests oil and gas equities may benefit from a tighter commodity backdrop and geopolitical risk premium.", "Natural gas fundamentals were described by Mizuho as constructive in recent commentary.", "The stock is near technical support levels, which could attract buyers if momentum stabilizes."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "Hedge funds are selling, and the selling amount increased 282.18% over the last quarter.", "No recent insider buying support; insiders are neutral.", "MACD remains negative and worsening, showing weak near-term trend.", "Analyst ratings are mostly Neutral to Underperform/Underweight/Sell, with several recent target cuts.", "No recent congress trading data and no evidence of influential-person buying interest."]
No usable latest-quarter financial snapshot was provided, so there is not enough data to assess recent revenue, EBITDA, EPS, or growth trends. The latest quarter season cannot be determined from the supplied financials because the snapshot errored out.
Wall Street is mixed but generally cautious-to-negative. Recent actions include Mizuho lowering its target to $42 and keeping Neutral, Barclays cutting to $35 and maintaining Underweight, BofA lowering to $34 with Underperform, Morgan Stanley lifting to $34 but keeping Underweight, Truist initiating Sell at $35, and JPMorgan remaining Neutral with a $39 target. The pros see upside from tighter oil markets, geopolitical risk premiums, and better cash flow potential for E&Ps, while the cons view focuses on weak inventory/production dynamics, limited Tier 1 inventory, and underwhelming stock re-rating. Overall, the Street does not show strong conviction to buy CNX here.
